ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 238 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2021. The put-call ratio across all filers is 1.29 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $2,361,000 | -49.2% | 20,735 | -38.2% | 0.02% | -46.9% |
| Q4 2020 | $4,648,000 | +48.5% | 33,571 | -11.8% | 0.03% | +52.4% |
| Q3 2020 | $3,129,000 | -7.3% | 38,071 | -11.8% | 0.02% | -22.2% |
| Q2 2020 | $3,377,000 | +90.3% | 43,171 | +8.0% | 0.03% | +68.8% |
| Q1 2020 | $1,775,000 | -10.4% | 39,971 | -13.8% | 0.02% | +14.3% |
| Q4 2019 | $1,981,000 | -1.4% | 46,371 | -1.3% | 0.01% | +16.7% |
| Q3 2019 | $2,009,000 | -33.8% | 46,971 | -1.7% | 0.01% | -42.9% |
| Q2 2019 | $3,033,000 | +158.3% | 47,771 | +182.1% | 0.02% | +133.3% |
| Q1 2019 | $1,174,000 | +72.9% | 16,935 | +8.3% | 0.01% | +50.0% |
| Q4 2018 | $679,000 | -48.6% | 15,635 | -9.6% | 0.01% | -40.0% |
| Q3 2018 | $1,321,000 | +11.7% | 17,298 | +12.3% | 0.01% | +25.0% |
| Q2 2018 | $1,183,000 | +47.9% | 15,398 | -1.9% | 0.01% | +60.0% |
| Q1 2018 | $800,000 | – | 15,698 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |